| | | IBRUTINIB
CAS:936563-96-1
Trade Name: 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
Formula: C25H24N6O2
APS936563961
440.50
Imbruvica, PCI 32765, PCI 32765-00, Ibrutinib, CRA 032765, JNJ 02,1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one, (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl Ibsrela
CAS:1234423-95-0
Formula: C50H66Cl4N8O10S2
PI1234423950
1145.00
17-[[[3-[(4S)-6,8-Dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]-N-[2-[2-[2-[[[3-[(4S)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]ethoxy]ethoxy]ethyl]-8-oxo-12,15-dioxa-2,7,9- IBUFENAC
CAS:1553-60-2
Trade Name: 2-[4-(2-methylpropyl)phenyl]acetic acid
Formula: C12H16O2
APS1553602
192.25
Benzeneacetic acid, 4-(2-methylpropyl)-, Isodilan, (p-Isobutylphenyl)acetic acid, Dytransin, NSC 99976, Acetic acid, (p-isobutylphenyl)- (8CI), 4-Isobutylphenylacetic acid, Medirex, 4-(2-Methylpropyl)benzeneacetic acid, 4-(2-Methylpropyl)ph IBUPROFEN
CAS:15687-27-1
Trade Name: 2-[4-(2-methylpropyl)phenyl]propanoic acid
Formula: C13H18O2
APS15687271
206.28
Ostarin, Dolgirid, Nurofen, Zafen, Algi-Flanderil, Suspren, Tabalon 400, Trendar, Tabalon, U 18753, Ibren, Ifen, Butylenin, Emodin, Codral Period Pain, Dolmaral, Dolocyl, (+/-)-Ibuprophen, Carol, Easifon, Ibufug, Haltran, Algiflex, Ostofen, IBUPROFEN
CAS:58560-75-1
Trade Name: 2-[4-(2-methylpropyl)phenyl]propanoic acid
Formula: C13H18O2
ACM58560751
206.28
ibuprofen, Motrin, Andran, Brufen, Liptan, Advil, Butylenin, Ibuprocin, Anflagen, Buburone, Medipren, Nobfelon, Lamidon, Pantrop, Rebugen, Dolgit, Ebufac, Nuprin, duralbuprofen, Butacortelone IBUPROFEN FOR PEAK IDENTIFICATION
CAS:15687-27-1
Trade Name: 2-[4-(2-methylpropyl)phenyl]propanoic acid
Formula: C13H18O2
APS15687271A
206.28
Tarein, Anafen, Ibuprocin, Lopane, Betaprofen, Relcofen, Ibu-Tab, Advil, Nuprin, Syntofene, Zafen, Atril 300, Nobfelon, Brufen, Rafen, Ibuflamar, Artril 300, Ibu-slow, Perofen, Proartinal, Zofen, dl-Ibuprofen, 2-(4'-Isobutylphenyl)propionic IBUTEROL
CAS:53034-85-8
Trade Name: [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate
Formula: C20H31NO5
ACM53034858
365.464 g/mol
Ibuterol, Ibuterolum, Terbutalindiisobutyrat, Ibuterolum [INN-Latin], CID68698, KWD 2058, KWD-2058, EINECS 258-311-4, 5-(2-(tert-Butylamino)-1-hydroxyethyl)-m-phenylene diisobutyrate, 2-Methylpropanoicacid 5-(2-((1,1-dimethylethyl)amino)-1- ICARISIDE B5
CAS:114226-08-3
Trade Name: (4S)-4-hydroxy-3,5,5-trimethyl-4-[(3R)-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
Formula: C19H32O8
ACM114226083
388.45258;g/mol
.blumenyl B +¦-D-glucopyranoside; .icariside B5; .dihydrovomifoliol-3GǦ-O-+¦-D-glucopyranoside; ICARISIDE B5; .dihydrovomifoliol-O-+¦-D-glucopyranose; (6S,9R)-6,9-dihydroxymegastigman-4-en-3-one 9-O-+¦-D-glucopyranoside; .blumenol C O ICBA
CAS:1207461-57-1
Formula: C78H16
ACM1207461571-1
952.99
1',1'',4',4''-Tetrahydro-di[1,4]methanonaphthaleno[1,2:2',3',56,60:2'',3''][5,6]fullerene-C60,C60 derivative, indene-C60 bisadduct ICBA
CAS:1207461-57-1
Formula: C78H16
ACM1207461571-1
952.99
1',1'',4',4''-Tetrahydro-di[1,4]methanonaphthaleno[1,2:2',3',56,60:2'',3''][5,6]fullerene-C60,C60 derivative, indene-C60 bisadduct ICBA
CAS:1207461-57-1
Formula: C78H16
ACM1207461571-1
952.99
1',1'',4',4''-Tetrahydro-di[1,4]methanonaphthaleno[1,2:2',3',56,60:2'',3''][5,6]fullerene-C60,C60 derivative, indene-C60 bisadduct ICBA
CAS:1207461-57-1
Formula: C78H16
NZs1207461571
952.96
1',1'',4',4''-Tetrahydro-di[1,4]methanonaphthaleno[1,2:2',3',56,60:2'',3''][5,6]fullerene-C60, C60 derivative, indene-C60 bisadduct ICH/USP Parenteral Combined-1 Target Elements: Mo @ 1500, Cr @ 1100, Ba @ 700, Sn @ 600, Cu @ 300, Li @ 250, Sb @ 90, Se @ 80, Ag @ 10, Tl @ 8 -¦g/mL in 5% HNO3, tr. HF
APS008887 ICI 162,846
CAS:84545-30-2
Trade Name: 5-[3-[[N-(2,2,2-trifluoroethyl)carbamimidoyl]amino]pyrazol-1-yl]pentanamide
Formula: C11H17F3N6O
ACM84545302
306.29
Tocris-0833, Ici 162846, CID134778, NCGC00024812-01, NCGC00024812-02, LS-128550, BRD-K66782112-001-01-2, 3-((Imino((2,2,2-trifluoroethyl)amino)methyl)amino)1H-pyrazole-1-pentamide, 1H-Pyrazole-1-pentanamide, 3-((imino((2,2,2-trifluoroethyl) ICLAZEPAM
CAS:57916-70-8
Trade Name: 7-chloro-1-[2-(cyclopropylmethoxy)ethyl]-5-phenyl-3H-1,4-benzodiazepin-2-one
Formula: C21H21ClN2O2
ACM57916708
368.862
Iclazepam, Iclazepamum, Iclazepamum [INN-Latin], UNII-FL061Q6NMC, CID68777, 7-Chloro-1-(2-(cyclopropylmethoxy)ethyl)-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one, 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(2-(cyclopropylmethoxy)ethyl)-1,3-d ICOMETHASONE
CAS:4647-20-5
Formula: C22H29ClO5
PR4647205
408.916
(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; ICOMETHASONE 21-MESYLATE
CAS:352315-75-4
Trade Name: [2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14
Formula: C23H31ClO7S
APS352315754
487.01
Pregna-1,4-diene-3,20-dione, 9-chloro-11,17-dihydroxy-16-methyl-21-[(methylsulfonyl)oxy]-, (11+¦,16+¦)-, Icomethasone 21-mesylate, 9-Chloro-11+¦,17-dihydroxy-16+¦-methyl-3,20-dioxopregna-1,4-dien-21-yl Methanesulfonate, Mometasone Furoate Imp. ICOS ligand Protein, Human, Recombinant
RHC-CD-2020
26.69 kDa (predicted); 47.51 kDa (reducing conditi
LICOS, inducible T-cell co-stimulator ligand, ICOSLG, ICOS-L, ICOSL, ICOS ligand, GL50, CD275, B7RP-1, B7RP1, B7-h2, B7H2 ICOS ligand Protein, Human, Recombinant (hFc)
RHC-CD-2113
53.7 kDa (predicted); 66-76 and 33 kDa (reducing c
LICOS, inducible T-cell co-stimulator ligand, ICOSLG, ICOS-L, ICOSL, ICOS ligand, GL50, CD275, B7RP-1, B7RP1, B7-h2, B7H2 ICOS ligand Protein, Human, Recombinant (His)
RHC-CD-1999
28 kDa (predicted); 42-62 kDa (reducing condition,
LICOS, inducible T-cell co-stimulator ligand, ICOSLG, ICOS-L, ICOSL, ICOS ligand, GL50, CD275, B7RP-1, B7RP1, B7-h2, B7H2 ICOS ligand Protein, Human, Recombinant (His), Biotinylated
RHC-CD-2043
28.1 kDa (predicted)
LICOS, inducible T-cell co-stimulator ligand, ICOSLG, ICOS-L, ICOSL, ICOS ligand, GL50, CD275, B7RP-1, B7RP1, B7-h2, B7H2 ICOS ligand Protein, Mouse, Recombinant (His & hFc)
RHC-CD-2143
54.3 kDa (predicted); 75-85 kDa (reducing conditio
LICOS, inducible T-cell co-stimulator ligand, Icoslg, ICOS-L, GL50-B, GL50, GI50, B7RP-1, B7-H2, B7h ICOS ligand Protein, Mouse, Recombinant (His)
RHC-CD-2383
27.8 kDa (predicted); 45-55 kDa (reducing conditio
LICOS, inducible T-cell co-stimulator ligand, Icoslg, ICOS-L, GL50-B, GL50, GI50, B7RP-1, B7-H2, B7h ICOSAMETHYLNONASILOXANE
CAS:2652-13-3
Trade Name: bis[[[[dimethyl(trimethylsilyloxy)silyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy]-dimethylsilane
Formula: C20H60O8Si9
ACM2652133
681.455 g/mol
Eicosamethylnonasiloxane, Icosamethylnonasiloxane, Nonasiloxane, eicosamethyl-, CID75858, EINECS 220-175-9, Nonasiloxane, 1,1,1,3,3,5,5,7,7,9,9,11,11,13,13,15,15,17,17,17-eicosamethyl-, 2652-13-3 ICOSAMETHYLNONASILOXANE
CAS:2652-13-3
Trade Name: bis[[[[dimethyl(trimethylsilyloxy)silyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy]-dimethylsilane
Formula: C20H60O8Si9
ACM2652133
681.455 g/mol
Eicosamethylnonasiloxane, Icosamethylnonasiloxane, Nonasiloxane, eicosamethyl-, CID75858, EINECS 220-175-9, Nonasiloxane, 1,1,1,3,3,5,5,7,7,9,9,11,11,13,13,15,15,17,17,17-eicosamethyl-, 2652-13-3 ICOSAN-1-YL HYDROGEN SULFATE
CAS:67633-89-0
Trade Name: icosyl hydrogen sulfate
Formula: C20H42O4S
ACM67633890-1
378.610080 [g/mol]
Arachidyl monosulfate, 1-Eicosanol, hydrogen sulfate, Icosan-1-yl hydrogen sulphate, 1-EICOSYLSULFATE, SODIUM, CID83208, 1-Eicosanol, 1-(hydrogen sulfate), EINECS 266-790-6, 67633-89-0 ICOSAN-1-YL HYDROGEN SULFATE
CAS:67633-89-0
Trade Name: icosyl hydrogen sulfate
Formula: C20H42O4S
ACM67633890
378.610080 [g/mol]
Arachidyl monosulfate, 1-Eicosanol, hydrogen sulfate, Icosan-1-yl hydrogen sulphate, 1-EICOSYLSULFATE, SODIUM, CID83208, 1-Eicosanol, 1-(hydrogen sulfate), EINECS 266-790-6, 67633-89-0 ICOSPIRAMIDE
CAS:79449-99-3
Trade Name: 2-[8-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-4-(4-fluorophenyl)-1-oxo-2,4,8-triazaspiro[4.5]decan-2-y
Formula: C28H31F2N5O2
ACM79449993
507.582
Icospiramide, Icospiramidum, Icospiramid, Icospiramida, Icospiramidum [Latin], Icospiramida [Spanish], UNII-H0N246YG4Y, CID71233, EINECS 279-161-6, 79449-99-3, 8-(cis-4-Cyano-4-(p-fluorophenyl)cyclohexyl)-1-(p-fluorophenyl)-4-oxo-1,3,8-tria ICP-MS CRQL Solution 1: Co, Mn @ 5; Ag, As, Be, Cd, Ni, Pb, Tl, V, Zn @ 10; Cr, Cu, Sb @ 20; Se @ 50; Ba @ 100; Al @ 300 -¦g/mL in 5% HNO3, tr. Tartaric Acid
APS008892 ICP-MS CRQL Solution 2: Ag, As, Be, Cd, Co, Mn, Ni, Pb, Tl, V @ 10; Cr, Cu, Sb, Zn @ 20; Se @ 50; Ba @ 100 -¦g/mL in 5% HNO3, tr. Tartaric Acid
APS008893 ICP-MS Dual Detector Solution: Al, Ba, Ce, Co, Cu, In, Li, Mg, Mn, Ni, Pb, Tb, U, Zn @ 200 -¦g/L in 2% HNO3
APS008894 ICP-MS P/A Tuning Mix 1: Y, Tb @ 2.5ug/mL; 6Li, Na, Al, Sc, Ti, V, Cr, Mn, Co, Cu, Sr, In, Ba, Lu, Ir, Bi, Tl, Th, U @ 5ug/mL; Mg, Ni, Ge, Mo, Ru, Pd, Sn, Sb, Pb @ 10ug/mL; Be, Zn, As, Cd @ 20 ug/mL in 20% HCl, tr. HF
APS008899 ICP-MS P/A Tuning Solution 1: As, Be, Cd, Zn @ 20-¦g/mL; Mg, Ni, Pb @ 10 -¦g/mL; Al, Ba, Bi, Co, Cr, Cu, In, 6Li, Lu, Mn, Na, Sc, Sr, Th, Tl, U, V @ 5-¦g/mL; Y, Yb @ 2.5 -¦g/mL in 2% HNO3
APS008900 ICP-MS Setup/Stability/Masscal Solution: Ba @ 10 -¦g/L; Al, Cd, Ce, Cr, Cu, In, Mg, Mn, Pb, Rh, Th @ 1 -¦g/L in 0.5% HCl
APS008905 ICP-MS Tuning Solution I: Ba, Be, Ce, Co, In, Li, Mg, Pb, Rh, Tl, U, Y @ 10 ug/mL in 2% HNO3 / 5% HCl
APS008911 ICP-MS Tuning/Mass Calibration Multi-Element Mix 3 (concentrate): 7Li, Be, Mg, Co, Y, In, Ba, Ce, Tb, Pb, U @ 10 ug/mL in 5% HNO3
APS001958 ICP-OES ICAL Solution: S @ 50 -¦g/mL; Ce, Cu, Eu, Fe, In, K, Ni, P, Si, Ti, V, Y, Zr @ 10-¦g/mL; Mn, Mo, Na, Sc @ 5-¦g/mL; Be, Li, Sr @ 2-¦g/mL; Ca @ 1 -¦g/mL in 2% HNO3 / 2% HCl
APS008919 Icraiin, food grade
CAS:489-32-7
Trade Name: 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxy
Formula: C33H40O15
DS489327
676.66
Ieariline; 5-Hydroxy-2-(4-Methoxyphenyl)-8-(3-Methylbut-2-En-1-Yl)-7-(((2S,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-2-Yl)Oxy)-3-(((2S,3R,4R,5R,6S)-3,4,5-Trihydroxy-6-Methyltetrahydro-2H-Pyran-2-Yl)Oxy)-4H-Chromen-4 ICS Analytes B: Pb, Se @ 5; As, Tl @ 10; Ag @ 20; Ba, Be, Co, Cr, Cu, Mn, V @ 50; Sb @ 60; Cd, Ni, Zn @ 100 -¦g/mL in 5% HNO3, tr. Tartaric Acid
APS008926 ICS Target Analytes B: Ag, Al, As, Ba, Be, Cd, Co, Cr, Cu, Mn, Ni, Pb, Sb, Se, Tl, V, Zn @ 10 -¦g/mL in 5% HNO3, tr. Tartaric Acid
APS008928 ICTEROGENIN
CAS:561-47-7
Trade Name: (4R,4aS,6aR,6aS,6bR,9S,12aR,14bR)-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-4-[(E)-2-methylbut-2-
Formula: C35H52O6
ACM561477
568.8 ICTEROGENIN
CAS:561-47-7
Trade Name: (4R,4aS,6aR,6aS,6bR,9S,12aR,14bR)-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-4-[(E)-2-methylbut-2-
Formula: C35H52O6
FFC-AR-561477
568.8
24-Hydroxy-22+¦-[[(Z)-2-methyl-1-oxo-2-butenyl]oxy]-3-oxo-olean-12-en-28-oic acid IDARUBICINOL
CAS:86189-66-4
Formula: C26H29NO9
ACM86189664
499.51
IDARUBICINOL;4-demethoxydaunorubicinol;5,12-naphthacenedione,7-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)ox;9(r*)))-lph;antibioticfce22723;y)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(1-hydroxyethyl)-,(7s-(7-alpha,9-a;(7S)-9+¦-(1-Hy IDARUBICINOL-D4 (MIXTURE OF DIASTEREOMERS)
Trade Name: (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(1,
Formula: C26D4H25NO9
APS008930
503.53
4-Demethoxydaunorubicinol-d4, Antibiotic FCE 22723-d4, 13-Dihydroidarubicin-d4, [7S-[7+¦,9+¦,9(R*)]]-7-[(3-Amino-2,3,6-trideoxy-+¦-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(1-hydroxyethyl)-5,12-naphthacenedione-d4,(7S, IDEBENONE-13C1,D3
Formula: C1813CH27D3O5
ACMA00048278
342.45
2-(10-Hydroxydecyl)-6-methoxy-5-(methoxy-13C1,d3)-3-methyl-2,5-cyclohexadiene-1,4-dione;2,3-Dimethoxy-6-(10-hydroxydecyl)-5-methyl-1,4-benzoquinone-13C1,d3;Avan-13C1,d3;CV 2619-13C1,d3;Daruma-13C1,d3 IDIC, 2,2'-((2Z,2'Z)-((4,4,9,9-tetrakis(p-hexylphenyl)-4,9-dihydro-s-dithiophene-2,7-diyl)bis(methylidene))-bis-(3-oxo-2,3-dihydro-1H-indene-2,1-dimethylene))dimalononitrile
CAS:1883441-92-6
Formula: C66H66N4O2S2
ACM1883441926-1
1011.39 IDIC-4Cl, 2,2'-((2Z,2'Z)-((4,4,9,9-tetravinyl-4,9-dihydro-s-indeno[1,2-b:5,6-b']dithiophene-2,7-diyl)bis(5,6-dichloro-3-(dicyanomethylidene)inden-1-one)
CAS:2361961-01-3
Formula: C66H62Cl4N4O2S2
ACM2361961013
1149.17 IDIC-4F, 2,2'-((2Z,2'Z)-((4,4,9,9-tetravinyl-4,9-dihydro-s-indolo[1,2-b:5,6-b']dithiophene-2,7-diyl)bis(5,6-difluoro-3-(dicyanomethylene)indene-1-one)
CAS:2229934-71-6
Formula: C66H62F4N4O2S2
ACM2229934716
1083.35 IDITOL
CAS:24557-79-7
Trade Name: (3S,4S,5R,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
Formula: C6H14O6
ACM24557797
182.1718
dextrose, Iditol, D-Talose, D-Talo-hexose, D-(+)-Talose, D-()-Talose, 86265_FLUKA, 86265_SIGMA, MolPort-003-939-282, CID441035, NCGC00166303-01, T0869, C06467, 24557-79-7, 2595-98-4 IDPH-791
CAS:98827-47-5
Trade Name: 2,4-dihydro-[1,2,4]triazolo[3,4-c][1,4]benzothiazin-1-one
Formula: C9H7N3OS
ACM98827475
205.236380 [g/mol]
2,4-dihydro-1H-s-triazolo<3,4-c>-1,4-benzothiazin-1-one; 2,4-dihydro-1H-benzo[b][1,2,4]triazolo[4,3-d][1,4]thiazin-1-one; 2,4-Dihydro-1H-(1,2,4)triazolo(3,4-c)(1,4)benzothiazin-1-one; Idph-791; 1-Oxo-2,4-dihydro(1,2,4)triazolo(3,4-c)(1,4)be IDRANAL IV FUER ANALYSE
CAS:145819-99-4
Trade Name: 2-[[2-[bis(carboxymethyl)amino]cyclohexyl]-(carboxymethyl)amino]acetic acid;hydrate
Formula: C14H22N2O8??-+H2O
ACM145819994
364.35
Glycine, N,N-1,2-cyclohexanediylbis[N-(carboxymethyl)-, monohydrate, 145819-99-4, CDTA hydrate, ACMC-20n4nc, AGN-PC-01ZLPZ, SureCN1825839, CTK0B2555, A806528, trans-1,2-CYCLOHEXANEDIAMINE-N,N,N,N-TETRAACETIC ACID, Glycine, N,N-1,2-cyclohexa IDT-2BR
CAS:2042521-91-3
ACM2042521913
1518.2
5,5'-[[4,4,9,9-Tetrakis(4-hexylphenyl)-4,9-dihydro-s-indaceno[1,2-b:5,6-b']dithiophene-2,7-diyl]bis(2,1,3-benzothiadiazole-7,4-diylmethylidyne)]bis[3-ethyl-2-thioxo-4-thiazolidinone],IDT-BT-R IDX-320-d5
ACMA00045059
809.93
(2S,13aR,14aS,16aS,Z)-2-((7-methoxy-8-methyl-2-(4-(trifluoromethyl)thiazol-2-yl)quinolin-4-yl)oxy)-7-(methyl-d3)-N-((1-methylcyclopropyl)sulfonyl)-6,16-dioxo-1,3,4,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocycl IFENPRODIL HEMITARTRATE
CAS:23210-58-4
Trade Name: 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol;(2R,3R)-2,3-dihydroxybutanedioic acid
Formula: 2C21H27NO2.C4H6O6
APS23210584
800.98
1-Piperidineethanol, +¦-(4-hydroxyphenyl)-+¦-methyl-4-(phenylmethyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (salt) (9CI), Ifenprodil tartrate, 1-Piperidineethanol, 4-benzyl-+¦-(p-hydroxyphenyl)-+¦-methyl-, tartrate (salt) (8CI), Ifenprodil L IFLAB-BB F0349-0482
CAS:78941-95-4
Trade Name: 5-chloro-8-methylquinoline
Formula: C10H8ClN
ACM78941954
177.63
5-chloro-8-methylquinoline, 78941-95-4, BD231292, ACMC-209pg2, AC1N12TG, SureCN2056205, 5-Chloro-8-methylquinoline,, Quinoline, 5-chloro-8-methyl-, CTK2G4714, MolPort-003-355-591, ANW-37248, AKOS001483093, AG-C-71796, MCULE-5859248043, AK-9 IFN gamma Protein, Human, Recombinant
RHC-CGF-0005
16.7 kDa (predicted); 21&25 kDa (reducing conditio
interferon, +¦, interferon, gamma, Interferon +¦, Interferon Gamma, IFN +¦, IFN gamma, IFI, IFG IFN gamma Protein, Human, Recombinant (His & Avi)
RHC-CGF-0013
19.1 kDa (predicted). Due to glycosylation, the pr
Interferon-+¦, Interferon-gamma, interferon, IFN+¦, IFN +¦/IFNG, IFN +¦, IFN gamma, IFI, IFG, gamma IFN gamma Protein, Human, Recombinant (His & Avi), Biotinylated
RHC-CGF-0025
19.1 kDa (predicted). Due to glycosylation, the pr
Interferon-+¦, Interferon-gamma, interferon, IFN+¦, IFN +¦/IFNG, IFN +¦, IFN gamma, IFI, IFG, gamma IFN-alpha 1/IFNA1 Protein, Human, Recombinant (hFc)
RHC-CGF-0077
46.14 kDa (predicted). Due to glycosylation, the p
LeIF D, Interferon +¦-D, Interferon +¦-1/13, Interferon +¦1, Interferon alpha-D, Interferon alpha-1/13, Interferon alpha 1, IFN-+¦-1/13, IFN-+¦-1, IFN+¦1, IFN-alpha-1/13, IFN-alpha-1, IFNalpha 1, IFNA1, IFN +¦1, IFN +¦ 1, IFN alpha1 IFN-alpha 1/IFNA1 Protein, Mouse, Recombinant (hFc)
RHC-CGF-0002
45.88 kDa (predicted). Due to glycosylation, the p
LeIF D, Interferon +¦-D, Interferon +¦-1/13, Interferon +¦1, Interferon alpha-D, Interferon alpha-1/13, Interferon alpha 1, IFN-+¦-1/13, IFN-+¦-1, IFN+¦1, IFN-alpha-1/13, IFN-alpha-1, IFNalpha 1, IFNA1, IFN +¦1, IFN +¦ 1, IFN alpha1 IFN-alpha 2/IFNA2 Protein, Mouse, Recombinant
RHC-CGF-0016
16 kDa (reducing condition)
LeIF A, Interferon +¦-A, Interferon +¦-2, Interferon Alpha-A, Interferon Alpha-2, IFN-+¦-2, IFN-Alpha-2, IFNA2, IFN +¦2 IFN-alpha 2a/IFNA2 Protein, Human, Recombinant
RHC-CGF-0012
16 kDa (reducing condition)
LeIF A, Interferon +¦-A, Interferon +¦-2, Interferon Alpha-A, Interferon Alpha-2, IFN-+¦-2, IFN-Alpha-2, IFNA2, IFN +¦2a IFN-alpha 2b/IFNA2 Protein, Human, Recombinant
RHC-CGF-0011
17 kDa (reducing condition)
LeIF A, Interferon +¦-A, Interferon +¦-2, Interferon Alpha-A, Interferon Alpha-2, IFN-+¦-2, IFN-Alpha-2, IFNA2, IFN +¦2b IFN-alpha 6/IFNA6 Protein, Human, Recombinant (His)
RHC-CGF-0026
18 kDa (reducing condition)
LeIF K, Interferon +¦-K, Interferon +¦-6, Interferon +¦-54, Interferon Alpha-K, Interferon Alpha-6, Interferon Alpha-54, IFN-+¦-6, IFN-Alpha-6, IFNA6, IFN +¦6 IFN-beta Protein, Human, Recombinant
RHC-CGF-0009
20 kDa (predicted); 20-23 kDa (reducing conditions
interferon, +¦1, fibroblast, interferon, beta 1, fibroblast, Interferon +¦, Interferon beta, IFN-+¦, IFN-beta, IFNB, IFF, IFB IFN-beta Protein, Human, Recombinant (hFc)
RHC-CGF-0008
46.7 kDa (predicted); 52 kDa (reducing condition,
interferon, +¦1, fibroblast, interferon, beta 1, fibroblast, Interferon +¦, Interferon beta, IFN-+¦, IFN-beta, IFNB, IFF, IFB IFN-beta Protein, Mouse, Recombinant
RHC-CGF-0004
20.3 kDa (predicted); 30 kDa (reducing conditions)
interferon, +¦1, fibroblast, interferon, beta 1, fibroblast, IFN-+¦, IFN-beta, IFNB, Ifb IFN-beta Protein, Mouse, Recombinant (hFc)
RHC-CGF-0056
46.7 kDa (predicted); 58 kDa (reducing condition,
interferon, +¦1, fibroblast, interferon, beta 1, fibroblast, IFN-+¦, IFN-beta, IFNB, Ifb IFN-omega Protein, Human, Recombinant (hFc)
RHC-CGF-0021
46.6 kDa (predicted); 50 kDa (reducing condition,
interferon, -ë 1, interferon, omega 1, interferon -ë-1, interferon omega-1, IFN--ë 1, IFN--ë, IFNW1, IFN-omega 1 IFN-omega Protein, Human, Recombinant (His)
RHC-CGF-0083
21.6 kDa (predicted); 22 kDa (reducing conditions)
interferon, -ë 1, interferon, omega 1, interferon -ë-1, interferon omega-1, IFN--ë 1, IFN--ë, IFNW1, IFN-omega 1 IFNAR1 Protein, Human, Recombinant (hFc)
RHC-RP-0538
74 kDa (predicted); 100-120 kDa (reducing conditio
interferon (+¦, +¦ and +¬) receptor 1, interferon (+¦, +¦ and -ë) receptor 1, interferon (alpha, beta and omega) receptor 1, IFRC, IFN-+¦-REC, IFNBR, IFNAR, IFN-alpha-REC, AVP IFNAR1 Protein, Human, Recombinant (His & Avi)
RHC-RP-0544
50.2 kDa (predicted). Due to glycosylation, the pr
IFRC, IFN-+¦-REC, IFN-+¦/+¦ R1, IFN-R-1, IFNbR1, IFNBR, IFN-aR1, IFNAR1, IFNAR, IFN-alpha-REC, IFN-alpha/+¦ R1, IFN-alpha/beta R1, IFN +¦/+¦ R1, CRF2-1, AVP IFNAR1 Protein, Human, Recombinant (His)
RHC-RP-0542
48.6 kDa (predicted); 77.8 kDa (reducing condition
interferon (+¦, +¦ and -ë) receptor 1, interferon (+¦, +¦ and +¬) receptor 1, interferon (alpha, beta and omega) receptor 1, IFRC, IFN-+¦-REC, IFNBR, IFNAR, IFN-alpha-REC, AVP IFNAR1 Protein, Mouse, Recombinant (hFc)
RHC-RP-0545
72.5 kDa (predicted). Due to glycosylation, the pr
IFRC, IFN-+¦-REC, IFN-+¦/+¦ R1, IFN-R-1, IFNbR1, IFNBR, IFN-aR1, IFNAR1, IFNAR, IFN-alpha-REC, IFN-alpha/+¦ R1, IFN-alpha/beta R1, IFN +¦/+¦ R1, CRF2-1, AVP IFNAR1 Protein, Mouse, Recombinant (His & Avi)
RHC-RP-0554
46.9 kDa (predicted). Due to glycosylation, the pr
IFRC, IFN-+¦-REC, IFN-+¦/+¦ R1, IFN-R-1, IFNbR1, IFNBR, IFN-aR1, IFNAR1, IFNAR, IFN-alpha-REC, IFN-alpha/+¦ R1, IFN-alpha/beta R1, IFN +¦/+¦ R1, CRF2-1, AVP IFNAR1 Protein, Mouse, Recombinant (His)
RHC-RP-0541
47 kDa (predicted); 55-60 kDa (reducing condition,
interferon (+¦, +¦ and -ë) receptor 1, interferon (+¦, +¦ and +¬) receptor 1, interferon (alpha, beta and omega) receptor 1, Infar, Ifrc, Ifnar, Ifar, CD118 IFNAR1 Protein, Rhesus macaque, Recombinant (His)
RHC-RP-0533
70-120 kDa (reducing condition)
+¦-type antiviral protein, +¦-type antiviral protein, IFN-+¦/+¦ receptor 1, IFN-+¦/+¦ R1, IFN-alpha/beta receptor 1, IFN-alpha/beta R1, IFN-al, human interferon-+¦ receptor (HuIFN-+¦-Rec)10IFRC, human interferon-alpha receptor (HuIFN-alpha-Rec)10IF IFNAR1, Protein, Human, Recombinant (His & Avi), Biotinylated
RHC-RP-0532
50.2 kDa (predicted). Due to glycosylation, the pr
IFRC, IFN-+¦-REC, IFN-+¦/+¦ R1, IFN-R-1, IFNbR1, IFNBR, IFN-aR1, IFNAR1, IFNAR, IFN-alpha-REC, IFN-alpha/+¦ R1, IFN-alpha/beta R1, IFN +¦/+¦ R1, CRF2-1, AVP IFNAR2 Protein, Cynomolgus, Recombinant (aa 27-243, His)
RHC-RP-0540
25.93 kDa (predicted). Due to glycosylation, the p
+¦ receptor10, +¦ receptor 2, IFN-+¦/+¦ R2, IFN-+¦, IFN-R-2, IFN-R, IFNbR2, IFNARB, IFNAR2, IFN-alpha/beta R2, IFN-alpha, IFNABR, IFN +¦/+¦ R2 IFNAR2 Protein, Human, Recombinant (aa 27-243, His)
RHC-RP-0531
25.8 kDa (predicted). Due to glycosylation, the pr
+¦ receptor10, +¦ receptor 2, IFN-+¦/+¦ R2, IFN-+¦, IFN-R-2, IFN-R, IFNbR2, IFNARB, IFNAR2, IFN-alpha/beta R2, IFN-alpha, IFNABR, IFN +¦/+¦ R2 IFNAR2 Protein, Human, Recombinant (hFc)
RHC-RP-0534
51.8 kDa (predicted); 65-75 kDa (reducing conditio
interferon (+¦, +¦ and -ë) receptor 2, interferon (+¦, +¦ and +¬) receptor 2, interferon (alpha, beta and omega) receptor 2, IFN-+¦-REC, IFN-R, IFNARB, IFN-alpha-REC, IFNABR IFNAR2 Protein, Human, Recombinant (His)
RHC-RP-0556
26.2 kDa (predicted); 45 kDa (reducing condition,
interferon (+¦, +¦ and -ë) receptor 2, interferon (+¦, +¦ and +¬) receptor 2, interferon (alpha, beta and omega) receptor 2, IFN-+¦-REC, IFN-R, IFNARB, IFN-alpha-REC, IFNABR IFNAR2 Protein, Human, Recombinant (His), Biotinylated
RHC-RP-0539
26.2 kDa (predicted)
interferon (+¦, +¦ and +¬) receptor 2, interferon (+¦, +¦ and -ë) receptor 2, interferon (alpha, beta and omega) receptor 2, IFN-+¦-REC, IFN-R, IFNARB, IFN-alpha-REC, IFNABR IFNGR1 Protein, Mouse, Recombinant (hFc)
RHC-RP-0551
53 kDa (predicted); 70-75 kDa (reducing condition,
Nktar, interferon +¦ receptor 1, interferon gamma receptor 1, IFN-+¦R, Ifngr, IFN-gammaR, Ifgr, CD119 IFOSFAMIDE IMPURITY F
CAS:40722-73-4
Trade Name: 2-chloro-3-(2-chloroethyl)-1,3,2++^{5}-oxazaphosphinane 2-oxide
Formula: C5H10Cl2NO2P
APS40722734
218.02
(RS)-2-chloro-3-(2-chloroethyl)-1,3,2-oxazaphosphinane 2-oxide, 2-Chloro-3-(2-chloroethyl)perhydro-1,3,2++5-oxazaphosphorin-2-one,2H-1,3,2-Oxazaphosphorine, 2-chloro-3-(2-chloroethyl)tetrahydro-, 2-oxide, Ifosfamide Imp. F Ig kappa Protein, Human, Recombinant (His)
RHC-RP-1908
14 kDa (reducing condition)
Immunoglobulin +¦, Immunoglobulin Kappa, IGKC, Ig +¦ chain C region CUM, Ig +¦ chain C region AG, Ig +¦ chain C region, Ig +¦, Ig kappa chain C region CUM, Ig kappa chain C region AG, Ig kappa chain C region Ig lambda constant 2 Protein, Human, Recombinant (His)
RHC-RP-1984
16 kDa (reducing condition)
MGC45681, MGC20392, immunoglobulin ++ constant 2 (Kern-Oz- marker), immunoglobulin lambda constant 2 (Kern-Oz- marker), IGLC2, IGLC, Ig ++ constant 2 Protein, Human, Recombinant (His), Ig ++ C Domain, Ig Lambda C Domain IGF1R/CD221 Protein, Cynomolgus, Recombinant (His)
RHC-CD-2751
80.59 kDa (alpha subunit) and 19.28 kDa (beta subu
MGC18216, MGC142172, MGC142170, JTK13, IGFR, IGFIR, IGF-I receptor, IGF-I R, IGF-1R, IGF1R, CD221 IGF1R/CD221 Protein, Human, Recombinant (aa 31-932, His & Avi), Biotinylated
RHC-CD-2799
105.8 kDa (alpha subunit) and 23 kDa (beta subunit
MGC18216, MGC142172, MGC142170, JTK13, IGFR, IGFIR, IGF-I receptor, IGF-I R, IGF-1R, IGF1R, CD221 IGF1R/CD221 Protein, Human, Recombinant (His & Avi)
RHC-CD-2519
105.8 kDa (alpha subunit) and 23 kDa (beta subunit
MGC18216, MGC142172, MGC142170, JTK13, IGFR, IGFIR, IGF-I receptor, IGF-I R, IGF-1R, IGF1R, CD221 IGF2BP-2 Protein, Human, Recombinant (His)
RHC-CGF-0874
43 kDa (reducing condition)
VICKZ2, VICKZ Family Member 2, Insulin-Like Growth Factor 2 mRNA-Binding Protein 2, IMP-2, IMP2, IGF-II mRNA-Binding Protein 2, IGF2BP2, IGF2 mRNA-Binding Protein 2, Hepatocellular Carcinoma Autoantigen p62 IGF2R Protein, Human, Recombinant (His & Avi), Biotinylated
RHC-CD-2634
164.90 kDa (predicted). Due to glycosylation, the
MPRI, MPR 300, M6PR, M6P/IGF2R, IGF-II receptor, CI-MPR, CD222 IGFBP-7 Protein, Human, Recombinant (aa 1-282, hFc)
RHC-CGF-0858
53.5 kDa (predicted); 65-70 kDa (reducing conditio
TAF, RAMSVPS, PSF, MAC25, insulin-like growth factor binding protein 7, IGFBPRP1, IGFBP-7v, IGFBP-7, IBP-7, FSTL2, AGM IGFBP-7 Protein, Human, Recombinant (aa 1-282, His)
RHC-CGF-0852
27.9 kDa (predicted); 36&32 kDa (reducing conditio
TAF, RAMSVPS, PSF, MAC25, insulin-like growth factor binding protein 7, IGFBPRP1, IGFBP-7v, IGFBP-7, IBP-7, FSTL2, AGM IGFBP-7 Protein, Human, Recombinant (aa 30-282, His)
RHC-CGF-0844
28.6 kDa (predicted); 36 kDa (reducing conditions)
TAF, RAMSVPS, PSF, MAC25, insulin-like growth factor binding protein 7, IGFBPRP1, IGFBP-7v, IGFBP-7, IBP-7, FSTL2, AGM IGFBP-7 Protein, Human, Recombinant (hFc & Avi), Biotinylated
RHC-CGF-0843
54.98 kDa (predicted); 62.49 kDa (reducing conditi
TAF, RAMSVPS, PSF, MAC25, insulin-like growth factor binding protein 7, IGFBPRP1, IGFBP-7v, IGFBP-7, IBP-7, FSTL2, AGM IGFBP-7 Protein, Human, Recombinant (hFc)
RHC-CGF-0853
53.20 kDa (predicted). Due to glycosylation, the p
TAF, RAMSVPS, PSF, MAC25, IGFBPRP1, IGFBP-7v, IGFBP-7, IBP7, FSTL2, AGM IGFBP-7 Protein, Human, Recombinant (His & Avi), Biotinylated
RHC-CGF-0878
29.37 kDa (predicted); 37.3 kDa (reducing conditio
TAF, RAMSVPS, PSF, MAC25, insulin-like growth factor binding protein 7, IGFBPRP1, IGFBP-7v, IGFBP-7, IBP-7, FSTL2, AGM IGFBP-7 Protein, Human, Recombinant (K95R, His)
RHC-CGF-0867
27.59 kDa (predicted); 34.02 kDa and 25.18 kDa (re
TAF, RAMSVPS, PSF, MAC25, insulin-like growth factor binding protein 7, IGFBPRP1, IGFBP-7v, IGFBP-7, IBP-7, FSTL2, AGM IGFBP-7 Protein, Mouse, Recombinant (hFc)
RHC-CGF-0876
53.03 kDa (predicted). Due to glycosylation, the p
TAF, RAMSVPS, PSF, MAC25, IGFBPRP1, IGFBP-7v, IGFBP-7, IBP7, FSTL2, AGM |
